No OS benefit with tasquinimod in mCRPC

The oral immunotherapy tasquinimod improved radiographic progression-free survival (rPFS) in men with metastatic castration-resistant prostate cancer (mCRPC), but the drug failed to improve overall...
Source: Family Practice News - Category: Primary Care Source Type: news